Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
This is a randomised study to examine whether high dose Sillymarin will be able to help improve fat-induced liver damage in the liver. The study hypothesis is that high dose Sillymarin will be able to reduce steato-hepatitis (fat-related liver inflammation) better than placebo.
Epistemonikos ID: 69d19e966ac571e5ef4e9b4753b52a9bf51de02b
First added on: May 11, 2024